Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

Sponsor
Peking Union Medical College Hospital
Study ID
NCT04047017
Phase
PHASE2
Status
Completed

Conditions

  • Gestational Trophoblastic Disease

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is to evaluate the efficacy and safety of camrelizumab plus apatinib in patients with high-risk chemo-refractory or relapsed GTN.

Key Dates

Start date
Aug 8, 2019
Status verified
Jul 2021
Primary completion
Mar 18, 2021
Completion
May 15, 2021

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Test group
    Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd

Primary Outcome Measure

ORR(objective response rate) [ Time Frame: Up to one years ]

Related Studies